Carcinogenicity Risk Assessment Supports the Chronic Safety of Dapagliflozin, an Inhibitor of Sodium–Glucose Co-Transporter 2, in the Treatment of Type 2 Diabetes Mellitus

INTRODUCTION: Dapagliflozin is a selective inhibitor of the sodium–glucose co-transporter 2 (SGLT2) that increases urinary glucose excretion to reduce hyperglycemia in the treatment of type 2 diabetes mellitus. A robust carcinogenicity risk assessment was undertaken to assess the chronic safety of d...

Descripción completa

Detalles Bibliográficos
Autores principales: Reilly, Timothy P., Graziano, Michael J., Janovitz, Evan B., Dorr, Thomas E., Fairchild, Craig, Lee, Francis, Chen, Jian, Wong, Tai, Whaley, Jean M., Tirmenstein, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065287/
https://www.ncbi.nlm.nih.gov/pubmed/24474422
http://dx.doi.org/10.1007/s13300-014-0053-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065287/
https://www.ncbi.nlm.nih.gov/pubmed/24474422
http://dx.doi.org/10.1007/s13300-014-0053-3

Ejemplares similares